02:02 PM EST, 11/13/2025 (MT Newswires) -- Cue Biopharma ( CUE ) entered an exclusive licensing deal giving ImmunoScape access to its clinical-stage Immuno-STAT molecules for oncology, ImmunoScape said Thursday.

The deal includes a total upfront payment of $15 million, with $10 million in fiscal Q4 and $5 million in November 2026, and gives Cue Biopharma ( CUE ) a 40% equity stake in ImmunoScape, according to a statement from Cue Biopharma ( CUE ) on Wednesday.

ImmunoScape said it will use the assets to advance its "Seed-and-Boost" platform, which is designed to expand cancer-targeting T cells in the body.

ImmunoScape also announced board additions, including Cue Biopharma ( CUE ) chief executive officer Usman Azam and immunotherapy veteran Adrian Bot, and appointed medical oncologist Pamela Munster to its scientific advisory board.

Shares of Cue Biopharma ( CUE ) were up 6% in recent Thursday trading.

Price: 0.71, Change: +0.04, Percent Change: +6.35